Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nanobiotix S.A. filings document foreign private issuer reporting for a late-stage clinical biotechnology company developing nanoparticle-based therapeutic platforms. Recent Form 6-K reports furnish press-release exhibits covering JNJ-1900 (NBTXR3) clinical and regulatory disclosures, Nanoprimer preclinical data, operating and financial updates, and responses to corporate-status speculation.
The filing record also documents capital-structure and governance information, including share capital, theoretical and exercisable voting rights reported under French market rules, material agreements tied to development and commercialization collaborations, and foreign private issuer status on Form 20-F for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix S.A. filed a report stating it will release its fourth quarter and full year 2025 financial and operational update on March 31, 2026, after the close of the U.S. market. The company will then host a conference call and webcast on April 1, 2026, at 8:00 a.m. EDT / 2:00 p.m. CEST, where senior management will review results and discuss recent business activities before taking questions. Connection details and a replay will be available in the investors section of the company’s website.
Nanobiotix S.A. filed a Form 6-K to share a press release responding to media speculation about a potential public take-over of the company. Nanobiotix states that, to the best of its knowledge, there is no intention by any party to acquire control of the company and that no process or assessment toward such a transaction is underway.
The company also notes that it has identified factual inaccuracies in the media report, which it says are not consistent with its most recent public disclosures. Beyond this clarification, the filing mainly reiterates Nanobiotix’s profile as a late-stage clinical biotechnology company developing nanotechnology-based therapies for cancer and other serious diseases.
Nanobiotix S.A. filed an update on its share capital and voting rights. As of February 28, 2026, the company had 48,494,528 shares outstanding, with 50,197,214 total theoretical voting rights and 50,175,096 exercisable voting rights, reflecting French regulatory disclosure requirements for threshold calculations.
Nanobiotix S.A. filed a Form 6-K to share a press release announcing its participation in several investor conferences in March. Company management, including CEO Laurent Levy and CFO & Business Officer Bart van Rhijn, will speak at healthcare and biotech events hosted by TD Cowen, UBS, Jefferies, and Leerink in Boston and Miami Beach. These appearances are intended to present the company’s late-stage nanotechnology-based oncology pipeline and broader platform to the investment community and other stakeholders.